Previous 10 | Next 10 |
VERVE-201 Preclinical Data Supports Advancement of Drug Candidate Toward Clinical Development for Homozygous Familial Hypercholesterolemia, with Initiation of Clinical Trial Anticipated in 2024 Data to be Presented During an Oral Presentation at the 2023 American College of Cardiolo...
Verve Therapeutics press release ( NASDAQ: VERV ): Q4 GAAP EPS of -$0.67 beats by $0.09 . Revenue of $1.01M beats by $0.57M . For further details see: Verve Therapeutics GAAP EPS of -$0.67 beats by $0.09, revenue of $1.01M beats by $0.57M
heart-1 Clinical Trial of VERVE-101 Ongoing in New Zealand and UK; Data from Dose Escalation Cohorts Expected in the Second Half of 2023 VERVE-201 Progressing Through Preclinical Development with Clinical Initiation Anticipated in 2024 Well-Capitalized with $554.8 Million Supporti...
Summary Verve Therapeutics has been stuck with a clinical hold. There is no good reason the hold will not be lifted, say within a year or less. While Verve was very highly valued at IPO and the hold has lowered prices, lifting the hold will help make a quick profit. ...
Summary Today, we are putting Beam Therapeutics back in the spotlight after an initial article on this gene editing name last summer. Beam Therapeutics' stock has sunk by a third since that avoid recommendation, but the shares have recently been upgraded by several analyst firms. Sh...
Summary Cathie Wood and her ARK Investment Management have just turned their backs on their worst year of performance since the inception of the investing firm. The market continued to systematically dissect any leftover enthusiasm in the growth and technology space, significantly hurti...
BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that VERVE-101 has been awarded the Innovation Passport for th...
Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...
The following slide deck was published by Verve Therapeutics, Inc. in conjunction with this event. For further details see: Verve Therapeutics (VERV) Presents at 41st Annual Healthcare Conference - Slideshow
Summary ARK Genomic Revolution ETF invests in small-cap and mid-cap companies engaged in genomic revolution, i.e., in the research of genomic sequencing, analysis, synthesis, or instrumentation. Alpha-generating stocks ARKG selects from time to time and backs for a longer time period ha...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...